Please login to the form below

Onglyza

This page shows the latest Onglyza news and features for those working in and with pharma, biotech and healthcare.

Those concerns have caused warnings to be imposed on some rival drugs, namely AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin).

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015. ... Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga
EU clears AZ's FDA-rejected diabetes combination

Qtern combines the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) with SGLT2 inhibitor Farxiga/Forixiga (saxagliptin), and is the second drug of its type on the market after ... Since then however, Onglyza and certain other DPP4
NICE backs freer use of SGLT2 inhibitors for diabetes

Importantly the recommendations put the SGLT2 inhibitors on a par with another newer class of diabetes drug - DPP-4 inhibitors such as MSD's Januvia (sitagliptin) and AstraZeneca's Onglyza (saxagliptin).
FDA rejects AZ's diabetes combination

The combination of DPP-4 inhibitor saxagliptin - sold by AZ as Onglyza - and SGLT2 inhibitor dapagliflozin (marketed as Farxiga/Forixiga) is considered to be a key component of the company's
The role of pharma in the digital world of patient and doctors

For us, that would be going to a website after being diagnosed with diabetes [AZ markets type II oral medicines Forxiga, Byetta, Bydureon and Onglyza], and make sure that here, we

More from news
Approximately 10 fully matching, plus 46 partially matching documents found.

Interview: Christopher Boulton, AstraZeneca

Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... As AZ can attest